Stock Events

Cidara Therapeutics 

$11.77
38
-$0.39-3.21% Tuesday 20:00

Statistics

Day High
12.27
Day Low
11.53
52W High
27.6
52W Low
10
Volume
32,988
Avg. Volume
60,107
Mkt Cap
53.69M
P/E Ratio
-1.04
Dividend Yield
-
Dividend
-

Earnings

22AprConfirmed
Q2 2022
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q1 2024
-2
-1.27
-0.55
0.18
Expected EPS
-2
Actual EPS
-0.8

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CDTX. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Analyst Ratings

23.67$Average Price Target
The highest estimate is $40.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

About

Health Technology
Biotechnology
Manufacturing
Biological Product (except Diagnostic) Manufacturing
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.
Show more...
CEO
Jeffrey Stein
Employees
69
Country
US
ISIN
US1717571079
WKN
000A14R2R

Listings